Virtual Reality Aniseikonia and Metamorphopsia Testing

ConditionsMetamorphopsia Aniseikonia

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorNYU Langone Health

About this trial

The purpose of this study is to assess whether the use of small, lightweight, portable virtual reality headset devices can provide a more accessible, reliable, contained, and convenient testing environment compared to previous platforms.

Many tests only assess distortions in one plane or meridian and may have confounding effects from factors such as external stimuli or the use of colored filters to selectively display images to each eye. The investigators hypothesize that this device will help minimize, if not get rid of, a lot of these confounding factors that exist currently.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Over 18 years of age

Have no reported visual distortions with a negative Amsler test; or

Have visual distortions with a positive Amsler grid test and an ocular history of one of the following: epiretinal membrane (ERM), age-related Macular degeneration (AMD), central serous retinopathy (CSR), diabetic macular edema (DME), cystoid macular edema (CME)

Ophthalmology residents, staff, and physicians

Disqualifiers

Eye pathology limiting view to the posterior pole to obtain adequate quality fundus photograph or OCT imaging in either eye

Impaired visual acuity with best-corrected visual acuity equal to or worse than 20/70

Motor deficits of the upper extremities

Trial design

Design model

Parallel

Treatments tested in this trial

Aegenta VR
Device
The Aegenta VR system is a custom software application designed to operate with a virtual reality (VR) headset platform, such as a smartphone paired with a Google Cardboard V2 viewer. The application presents visual stimuli to each eye and allows users to identify perceived distortions and magnification changes. These responses are used to generate quantitative measures of metamorphopsia and aniseikonia.

Treatment groups

100 Participants

are divided into 2 treatment groups

Group A: Amsler-negative participantsExperimental treatment 1 intervention

Group B: Amsler-positive participantsExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Aegenta M-Test Score

Aegenta device output - a quantitative measure intended to capture the degree of metamorphopsia.

Time frame

Day 0

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

NYU Langone Health

Lead sponsor

Source ClinicalTrials.gov

Apply now